Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial

Guillaume Marquis-Gravel, Matthew T. Roe, Holly R. Robertson, Robert A. Harrington, Michael J. Pencina, Lisa G. Berdan, Bradley G. Hammill, Madelaine Faulkner, Daniel Munõz, Gregg C. Fonarow, Brahmajee K. Nallamothu, Dan J. Fintel, Daniel E. Ford, Li Zhou, Sarah E. Daugherty, Elizabeth Nauman, Jennifer Kraschnewski, Faraz S. Ahmad, Catherine P. Benziger, Kevin HaynesJ. Greg Merritt, Thomas Metkus, Sunil Kripalani, Kamal Gupta, Raj C. Shah, James C. McClay, Richard N. Re, Carol Geary, Brent C. Lampert, Steven M. Bradley, Sandeep K. Jain, Hani Seifein, Jeff Whittle, Véronique L. Roger, Mark B. Effron, Giselle Alvarado, Ythan H. Goldberg, Jeffrey L. Vanwormer, Saket Girotra, Peter Farrehi, Kathleen M. McTigue, Russell Rothman, Adrian F. Hernandez, W. Schuyler Jones

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


Importance: Determining the right dosage of aspirin for the secondary prevention treatment of atherosclerotic cardiovascular disease (ASCVD) remains an unanswered and critical question. Objective: To report the rationale and design for a randomized clinical trial to determine the optimal dosage of aspirin to be used for secondary prevention of ASCVD, using an innovative research method. Design, Setting, and Participants: This pragmatic, open-label, patient-centered, randomized clinical trial is being conducted in 15000 patients within the National Patient-Centered Clinical Research Network (PCORnet), a distributed research network of partners including clinical research networks, health plan research networks, and patient-powered research networks across the United States. Patients with established ASCVD treated in routine clinical practice within the network are eligible. Patient recruitment began in April 2016. Enrollment was completed in June 2019. Final follow-up is expected to be completed by June 2020. Interventions: Participants are randomized on a web platform in a 1:1 fashion to either 81 mg or 325 mg of aspirin daily. Main Outcomes and Measures: The primary efficacy end point is the composite of all-cause mortality, hospitalization for nonfatal myocardial infarction, or hospitalization for a nonfatal stroke. The primary safety end point is hospitalization for major bleeding associated with a blood-product transfusion. End points are captured through regular queries of the health systems' common data model within the structure of PCORnet's distributed data environment. Conclusions and Relevance: As a pragmatic study and the first interventional trial conducted within the PCORnet electronic data infrastructure, this trial is testing several unique and innovative operational approaches that have the potential to disrupt and transform the conduct of future patient-centered randomized clinical trials by evaluating treatments integrated in clinical practice while at the same time determining the optimal dosage of aspirin for secondary prevention of ASCVD. Trial Registration: ClinicalTrials.gov

Original languageEnglish (US)
Pages (from-to)598-607
Number of pages10
JournalJAMA cardiology
Issue number5
StatePublished - May 2020

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial'. Together they form a unique fingerprint.

Cite this